Literature DB >> 11515884

Tranexamic acid in off-pump coronary surgery: a preliminary, randomized, double-blind, placebo-controlled study.

V Casati1, C Gerli, A Franco, G Torri, A D'Angelo, S Benussi, O Alfieri.   

Abstract

BACKGROUND: We evaluated the hemostatic effects of tranexamic acid, a synthetic antifibrinolytic drug, in patients undergoing beating-heart coronary surgery.
METHODS: Forty consecutive patients were in a double-blind manner, prospectively randomized into two groups: 20 patients received tranexamic acid (bolus of 1 g before skin incision, followed by continuous infusion of 400 mg/hr during surgery), and 20 patients received saline. As primary outcomes, bleeding and allogeneic transfusions were considered. D-dimer and fibrinogen plasma levels were also evaluated to monitor the activation of fibrinolysis. Major postoperative thrombotic events, as a potential consequence of antifibrinolytic treatment, were recorded.
RESULTS: The treatment group had significantly lower postoperative bleeding (median [25th to 75th percentiles]: 400 mL [337 to 490 mL] vs 650 ml [550 to 862 mL], p < 0.0001), lower need for allogeneic blood products (1,200 vs 5,300 mL, p < 0.001), and lower postoperative D-dimer plasma levels. No postoperative thrombotic complications were observed in either group.
CONCLUSIONS: In this initial series of patients undergoing off-pump coronary surgery, tranexamic acid appears to be effective in reducing postoperative bleeding and the need for allogeneic blood products.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11515884     DOI: 10.1016/s0003-4975(01)02802-8

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  8 in total

Review 1.  Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery.

Authors:  Robert J Porte; Frank W G Leebeek
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.

Authors:  David A Henry; Paul A Carless; Annette J Moxey; Dianne O'Connell; Barrie J Stokes; Dean A Fergusson; Katharine Ker
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

3.  Heparin anticoagulation in patients undergoing off-pump and on-pump coronary bypass surgery.

Authors:  Kenichi A Tanaka; Vinod H Thourani; Willis H Williams; Peggy G Duke; Jerrold H Levy; Robert A Guyton; John D Puskas
Journal:  J Anesth       Date:  2007-08-01       Impact factor: 2.078

4.  Association of Intravenous Tranexamic Acid With Thromboembolic Events and Mortality: A Systematic Review, Meta-analysis, and Meta-regression.

Authors:  Isabel Taeuber; Stephanie Weibel; Eva Herrmann; Vanessa Neef; Tobias Schlesinger; Peter Kranke; Leila Messroghli; Kai Zacharowski; Suma Choorapoikayil; Patrick Meybohm
Journal:  JAMA Surg       Date:  2021-04-14       Impact factor: 14.766

Review 5.  Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2012-03-26       Impact factor: 11.431

6.  Prophylactic intraoperative tranexamic acid administration and postoperative blood loss after transapical aortic valve implantation.

Authors:  Navid Madershahian; Maximilian Scherner; Roman Pfister; Tanja Rudolph; Antje C Deppe; Ingo Slottosch; Elmar Kuhn; Yeong-Hoon Choi; Thorsten Wahlers
Journal:  J Cardiothorac Surg       Date:  2015-03-28       Impact factor: 1.637

7.  The safety and efficiency of intravenous administration of tranexamic acid in coronary artery bypass grafting (CABG): a meta-analysis of 28 randomized controlled trials.

Authors:  Yanting Zhang; Yun Bai; Minmin Chen; Youfa Zhou; Xin Yu; Haiyan Zhou; Gang Chen
Journal:  BMC Anesthesiol       Date:  2019-06-14       Impact factor: 2.217

8.  Different dose regimes and administration methods of tranexamic acid in cardiac surgery: a meta-analysis of randomized trials.

Authors:  Jingfei Guo; Xurong Gao; Yan Ma; Huran Lv; Wenjun Hu; Shijie Zhang; Hongwen Ji; Guyan Wang; Jia Shi
Journal:  BMC Anesthesiol       Date:  2019-07-15       Impact factor: 2.217

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.